![Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis - Piehl - 2021 - Journal of Internal Medicine - Wiley Online Library Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis - Piehl - 2021 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/0ab46981-c083-4a7d-8ad7-122cdd1a9cc1/joim13215-fig-0001-m.jpg)
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis - Piehl - 2021 - Journal of Internal Medicine - Wiley Online Library
![Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals - ScienceDirect Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2211034821000444-gr1.jpg)
Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals - ScienceDirect
![Frontiers | Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome | Immunology Frontiers | Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome | Immunology](https://www.frontiersin.org/files/Articles/866092/fimmu-13-866092-HTML-r1/image_m/fimmu-13-866092-g001.jpg)
Frontiers | Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome | Immunology
![Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial - The Lancet Neurology Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2e3cbd4e-6095-448f-9448-b8a3500cabab/gr1.gif)
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial - The Lancet Neurology
![Prediction of disease progression and outcomes in multiple sclerosis with machine learning | Scientific Reports Prediction of disease progression and outcomes in multiple sclerosis with machine learning | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-78212-6/MediaObjects/41598_2020_78212_Fig1_HTML.png)
Prediction of disease progression and outcomes in multiple sclerosis with machine learning | Scientific Reports
![Cureus | Effectiveness of Anti-Cluster of Differentiation 20 as a Disease-Modifying Therapy in Multiple Sclerosis Across Its Different Phenotypes at the University Hospital of Caen Cureus | Effectiveness of Anti-Cluster of Differentiation 20 as a Disease-Modifying Therapy in Multiple Sclerosis Across Its Different Phenotypes at the University Hospital of Caen](https://assets.cureus.com/uploads/figure/file/315098/f1468ac08b1c11ecbcbe399ecccfda4a-Untitled.png)
Cureus | Effectiveness of Anti-Cluster of Differentiation 20 as a Disease-Modifying Therapy in Multiple Sclerosis Across Its Different Phenotypes at the University Hospital of Caen
![Assessing Disease Activity and Progression in Patients with Relapsing–Remitting Multiple Sclerosis: Interviews with Two Key Opinion Leaders - European Medical Journal Assessing Disease Activity and Progression in Patients with Relapsing–Remitting Multiple Sclerosis: Interviews with Two Key Opinion Leaders - European Medical Journal](https://emj.emg-health.com/wp-content/uploads/sites/2/2021/10/Figure-1-Multiple-sclerosis-disease-pathology.jpg)
Assessing Disease Activity and Progression in Patients with Relapsing–Remitting Multiple Sclerosis: Interviews with Two Key Opinion Leaders - European Medical Journal
![Ten-year disease progression in multiple sclerosis: walking declines more rapidly than arm and hand function - Multiple Sclerosis and Related Disorders Ten-year disease progression in multiple sclerosis: walking declines more rapidly than arm and hand function - Multiple Sclerosis and Related Disorders](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/83a98a3d-41c4-4f58-9640-f80555e7c440/gr1.jpg)
Ten-year disease progression in multiple sclerosis: walking declines more rapidly than arm and hand function - Multiple Sclerosis and Related Disorders
![Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines - Multiple Sclerosis and Related Disorders Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines - Multiple Sclerosis and Related Disorders](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/27d3fd67-8f1f-4889-b9c9-58bf70391a35/gr1.jpg)